Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis
OBJECTIVE To determine whether long term doxycycline improves symptoms in patients with chronic seronegative or reactive arthritis. METHODS A randomised, triple blind, controlled clinical trial of three months' treatment with doxycycline or placebo of patients with chronic reactive or seronegat...
Gespeichert in:
| Veröffentlicht in: | Annals of the rheumatic diseases 2001-12, Vol.60 (12), p.1088-1094 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1094 |
|---|---|
| container_issue | 12 |
| container_start_page | 1088 |
| container_title | Annals of the rheumatic diseases |
| container_volume | 60 |
| creator | Smieja, M MacPherson, D W Kean, W Schmuck, M L Goldsmith, C H Buchanan, W Hart, L E Mahony, J B |
| description | OBJECTIVE To determine whether long term doxycycline improves symptoms in patients with chronic seronegative or reactive arthritis. METHODS A randomised, triple blind, controlled clinical trial of three months' treatment with doxycycline or placebo of patients with chronic reactive or seronegative arthritis was conducted. The primary study end points were three month pain and functional status measured by a self administered Arthritis Impact Measurement Scales version 2 (AIMS2) quality of life questionnaire. Secondary end points were pain and functional status at 6–12 months, three month rheumatologist assessed joint count, pain, and arthritis activity, and treatment efficacy in those with previous exposure to chlamydia. RESULTS Of 60 patients randomly allocated to receive doxycycline or placebo, results from 37 were evaluable at three months. Groups were well balanced for major prognostic variables. Doxycycline had no detectable effect at three months on pain change scores (mean difference 1.5, 95% CI −1.2 to 4.2, p=0.25) or composite functional change scores (mean difference 0.8, 95% CI −5.6 to 7.1, p=0.81). Furthermore, there were no differences in secondary study end points, and no apparent treatment effect in patients with previous chlamydia infection. CONCLUSION Three months' treatment with doxycycline did not improve pain or functional status in patients with chronic reactive or seronegative arthritis. |
| doi_str_mv | 10.1136/ard.60.12.1088 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1753446</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A80771926</galeid><sourcerecordid>A80771926</sourcerecordid><originalsourceid>FETCH-LOGICAL-b591t-1f13f3f3a4479ac940e02add466fa3af640ad778a34d8693558fba5d246ff0993</originalsourceid><addsrcrecordid>eNqFkd9rFDEQx4Mo9qy--igL4oPQPZNsNsm-COWwVSkVf_U1zObHXc7dzZnsld5_b449egoFmYeZZD75ZoYvQi8JnhNS8XcQzZznms4JlvIRmhHGZUkxx4_RDGNclazh4gQ9S2mdj1gS-RSdECJww5icIfUNBhN6n6w5K9rOD2ZfbDrQtg2FDsMYQ9dZU4zRQ1cEV5hwt9M7nVFbuBALvYph8LpINme7hNHf2gLiuIp-9Ok5euKgS_bFIZ-inxcffiw-lldfLj8tzq_Ktm7IWBJHKpcDGBMN6IZhiykYwzh3UIHjDIMRQkLFjORNVdfStVAbyrhzuGmqU_R-0t1s294abfPg0KlN9D3EnQrg1b-dwa_UMtwqIuqKMZ4FXh8EYvi9tWlU67CNQ545I0JiXk3fnE3UEjqr_OBCFtNLO9ismdd3Pl-fSywEaehetHwAz2Fs7_VD_HzidQwpRevuFyBY7f1W2W_Fc03V3u_84NXfax_xg8EZeHMAIGnoXIRB-3TkGKG0ZvQ4qU-jvbvvQ_yluKhEra5vFqq5vrj5_pV-VpeZfzvxbb_-35B_ABgb0OY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1778063099</pqid></control><display><type>article</type><title>Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Smieja, M ; MacPherson, D W ; Kean, W ; Schmuck, M L ; Goldsmith, C H ; Buchanan, W ; Hart, L E ; Mahony, J B</creator><creatorcontrib>Smieja, M ; MacPherson, D W ; Kean, W ; Schmuck, M L ; Goldsmith, C H ; Buchanan, W ; Hart, L E ; Mahony, J B</creatorcontrib><description>OBJECTIVE To determine whether long term doxycycline improves symptoms in patients with chronic seronegative or reactive arthritis. METHODS A randomised, triple blind, controlled clinical trial of three months' treatment with doxycycline or placebo of patients with chronic reactive or seronegative arthritis was conducted. The primary study end points were three month pain and functional status measured by a self administered Arthritis Impact Measurement Scales version 2 (AIMS2) quality of life questionnaire. Secondary end points were pain and functional status at 6–12 months, three month rheumatologist assessed joint count, pain, and arthritis activity, and treatment efficacy in those with previous exposure to chlamydia. RESULTS Of 60 patients randomly allocated to receive doxycycline or placebo, results from 37 were evaluable at three months. Groups were well balanced for major prognostic variables. Doxycycline had no detectable effect at three months on pain change scores (mean difference 1.5, 95% CI −1.2 to 4.2, p=0.25) or composite functional change scores (mean difference 0.8, 95% CI −5.6 to 7.1, p=0.81). Furthermore, there were no differences in secondary study end points, and no apparent treatment effect in patients with previous chlamydia infection. CONCLUSION Three months' treatment with doxycycline did not improve pain or functional status in patients with chronic reactive or seronegative arthritis.</description><identifier>ISSN: 0003-4967</identifier><identifier>EISSN: 1468-2060</identifier><identifier>DOI: 10.1136/ard.60.12.1088</identifier><identifier>PMID: 11709448</identifier><identifier>CODEN: ARDIAO</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><subject>Adolescent ; Adult ; Aged ; Anti-Bacterial Agents - adverse effects ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Arthritis ; Arthritis - drug therapy ; Arthritis - physiopathology ; Arthritis, Reactive - drug therapy ; Arthritis, Reactive - physiopathology ; Biological and medical sciences ; Bones, joints and connective tissue. Antiinflammatory agents ; Case reports ; Chlamydia ; Chronic Disease ; Double-Blind Method ; Doxycycline ; Doxycycline - adverse effects ; Doxycycline - therapeutic use ; Drug therapy ; Evaluation ; Female ; Follow-Up Studies ; Health Status Indicators ; Humans ; Infections ; Laboratories ; Male ; Medical sciences ; Middle Aged ; Pain ; Pain Measurement ; Patient Compliance ; Patients ; Pharmacology. Drug treatments ; Physicians ; Quality of Life ; Questionnaires ; Randomised Controlled Trial ; Reiter's syndrome ; seronegative arthritis ; Surveys and Questionnaires ; Treatment Outcome ; Variance analysis</subject><ispartof>Annals of the rheumatic diseases, 2001-12, Vol.60 (12), p.1088-1094</ispartof><rights>Annals of the Rheumatic Diseases</rights><rights>2002 INIST-CNRS</rights><rights>COPYRIGHT 2001 BMJ Publishing Group Ltd.</rights><rights>Copyright: 2001 Annals of the Rheumatic Diseases</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b591t-1f13f3f3a4479ac940e02add466fa3af640ad778a34d8693558fba5d246ff0993</citedby><cites>FETCH-LOGICAL-b591t-1f13f3f3a4479ac940e02add466fa3af640ad778a34d8693558fba5d246ff0993</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1753446/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1753446/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14122542$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11709448$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smieja, M</creatorcontrib><creatorcontrib>MacPherson, D W</creatorcontrib><creatorcontrib>Kean, W</creatorcontrib><creatorcontrib>Schmuck, M L</creatorcontrib><creatorcontrib>Goldsmith, C H</creatorcontrib><creatorcontrib>Buchanan, W</creatorcontrib><creatorcontrib>Hart, L E</creatorcontrib><creatorcontrib>Mahony, J B</creatorcontrib><title>Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis</title><title>Annals of the rheumatic diseases</title><addtitle>Ann Rheum Dis</addtitle><description>OBJECTIVE To determine whether long term doxycycline improves symptoms in patients with chronic seronegative or reactive arthritis. METHODS A randomised, triple blind, controlled clinical trial of three months' treatment with doxycycline or placebo of patients with chronic reactive or seronegative arthritis was conducted. The primary study end points were three month pain and functional status measured by a self administered Arthritis Impact Measurement Scales version 2 (AIMS2) quality of life questionnaire. Secondary end points were pain and functional status at 6–12 months, three month rheumatologist assessed joint count, pain, and arthritis activity, and treatment efficacy in those with previous exposure to chlamydia. RESULTS Of 60 patients randomly allocated to receive doxycycline or placebo, results from 37 were evaluable at three months. Groups were well balanced for major prognostic variables. Doxycycline had no detectable effect at three months on pain change scores (mean difference 1.5, 95% CI −1.2 to 4.2, p=0.25) or composite functional change scores (mean difference 0.8, 95% CI −5.6 to 7.1, p=0.81). Furthermore, there were no differences in secondary study end points, and no apparent treatment effect in patients with previous chlamydia infection. CONCLUSION Three months' treatment with doxycycline did not improve pain or functional status in patients with chronic reactive or seronegative arthritis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Anti-Bacterial Agents - adverse effects</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Arthritis</subject><subject>Arthritis - drug therapy</subject><subject>Arthritis - physiopathology</subject><subject>Arthritis, Reactive - drug therapy</subject><subject>Arthritis, Reactive - physiopathology</subject><subject>Biological and medical sciences</subject><subject>Bones, joints and connective tissue. Antiinflammatory agents</subject><subject>Case reports</subject><subject>Chlamydia</subject><subject>Chronic Disease</subject><subject>Double-Blind Method</subject><subject>Doxycycline</subject><subject>Doxycycline - adverse effects</subject><subject>Doxycycline - therapeutic use</subject><subject>Drug therapy</subject><subject>Evaluation</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Health Status Indicators</subject><subject>Humans</subject><subject>Infections</subject><subject>Laboratories</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pain</subject><subject>Pain Measurement</subject><subject>Patient Compliance</subject><subject>Patients</subject><subject>Pharmacology. Drug treatments</subject><subject>Physicians</subject><subject>Quality of Life</subject><subject>Questionnaires</subject><subject>Randomised Controlled Trial</subject><subject>Reiter's syndrome</subject><subject>seronegative arthritis</subject><subject>Surveys and Questionnaires</subject><subject>Treatment Outcome</subject><subject>Variance analysis</subject><issn>0003-4967</issn><issn>1468-2060</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkd9rFDEQx4Mo9qy--igL4oPQPZNsNsm-COWwVSkVf_U1zObHXc7dzZnsld5_b449egoFmYeZZD75ZoYvQi8JnhNS8XcQzZznms4JlvIRmhHGZUkxx4_RDGNclazh4gQ9S2mdj1gS-RSdECJww5icIfUNBhN6n6w5K9rOD2ZfbDrQtg2FDsMYQ9dZU4zRQ1cEV5hwt9M7nVFbuBALvYph8LpINme7hNHf2gLiuIp-9Ok5euKgS_bFIZ-inxcffiw-lldfLj8tzq_Ktm7IWBJHKpcDGBMN6IZhiykYwzh3UIHjDIMRQkLFjORNVdfStVAbyrhzuGmqU_R-0t1s294abfPg0KlN9D3EnQrg1b-dwa_UMtwqIuqKMZ4FXh8EYvi9tWlU67CNQ545I0JiXk3fnE3UEjqr_OBCFtNLO9ismdd3Pl-fSywEaehetHwAz2Fs7_VD_HzidQwpRevuFyBY7f1W2W_Fc03V3u_84NXfax_xg8EZeHMAIGnoXIRB-3TkGKG0ZvQ4qU-jvbvvQ_yluKhEra5vFqq5vrj5_pV-VpeZfzvxbb_-35B_ABgb0OY</recordid><startdate>20011201</startdate><enddate>20011201</enddate><creator>Smieja, M</creator><creator>MacPherson, D W</creator><creator>Kean, W</creator><creator>Schmuck, M L</creator><creator>Goldsmith, C H</creator><creator>Buchanan, W</creator><creator>Hart, L E</creator><creator>Mahony, J B</creator><general>BMJ Publishing Group Ltd and European League Against Rheumatism</general><general>BMJ</general><general>BMJ Publishing Group Ltd</general><general>Elsevier Limited</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>5PM</scope></search><sort><creationdate>20011201</creationdate><title>Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis</title><author>Smieja, M ; MacPherson, D W ; Kean, W ; Schmuck, M L ; Goldsmith, C H ; Buchanan, W ; Hart, L E ; Mahony, J B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b591t-1f13f3f3a4479ac940e02add466fa3af640ad778a34d8693558fba5d246ff0993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Anti-Bacterial Agents - adverse effects</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Arthritis</topic><topic>Arthritis - drug therapy</topic><topic>Arthritis - physiopathology</topic><topic>Arthritis, Reactive - drug therapy</topic><topic>Arthritis, Reactive - physiopathology</topic><topic>Biological and medical sciences</topic><topic>Bones, joints and connective tissue. Antiinflammatory agents</topic><topic>Case reports</topic><topic>Chlamydia</topic><topic>Chronic Disease</topic><topic>Double-Blind Method</topic><topic>Doxycycline</topic><topic>Doxycycline - adverse effects</topic><topic>Doxycycline - therapeutic use</topic><topic>Drug therapy</topic><topic>Evaluation</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Health Status Indicators</topic><topic>Humans</topic><topic>Infections</topic><topic>Laboratories</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pain</topic><topic>Pain Measurement</topic><topic>Patient Compliance</topic><topic>Patients</topic><topic>Pharmacology. Drug treatments</topic><topic>Physicians</topic><topic>Quality of Life</topic><topic>Questionnaires</topic><topic>Randomised Controlled Trial</topic><topic>Reiter's syndrome</topic><topic>seronegative arthritis</topic><topic>Surveys and Questionnaires</topic><topic>Treatment Outcome</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smieja, M</creatorcontrib><creatorcontrib>MacPherson, D W</creatorcontrib><creatorcontrib>Kean, W</creatorcontrib><creatorcontrib>Schmuck, M L</creatorcontrib><creatorcontrib>Goldsmith, C H</creatorcontrib><creatorcontrib>Buchanan, W</creatorcontrib><creatorcontrib>Hart, L E</creatorcontrib><creatorcontrib>Mahony, J B</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of the rheumatic diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smieja, M</au><au>MacPherson, D W</au><au>Kean, W</au><au>Schmuck, M L</au><au>Goldsmith, C H</au><au>Buchanan, W</au><au>Hart, L E</au><au>Mahony, J B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis</atitle><jtitle>Annals of the rheumatic diseases</jtitle><addtitle>Ann Rheum Dis</addtitle><date>2001-12-01</date><risdate>2001</risdate><volume>60</volume><issue>12</issue><spage>1088</spage><epage>1094</epage><pages>1088-1094</pages><issn>0003-4967</issn><eissn>1468-2060</eissn><coden>ARDIAO</coden><abstract>OBJECTIVE To determine whether long term doxycycline improves symptoms in patients with chronic seronegative or reactive arthritis. METHODS A randomised, triple blind, controlled clinical trial of three months' treatment with doxycycline or placebo of patients with chronic reactive or seronegative arthritis was conducted. The primary study end points were three month pain and functional status measured by a self administered Arthritis Impact Measurement Scales version 2 (AIMS2) quality of life questionnaire. Secondary end points were pain and functional status at 6–12 months, three month rheumatologist assessed joint count, pain, and arthritis activity, and treatment efficacy in those with previous exposure to chlamydia. RESULTS Of 60 patients randomly allocated to receive doxycycline or placebo, results from 37 were evaluable at three months. Groups were well balanced for major prognostic variables. Doxycycline had no detectable effect at three months on pain change scores (mean difference 1.5, 95% CI −1.2 to 4.2, p=0.25) or composite functional change scores (mean difference 0.8, 95% CI −5.6 to 7.1, p=0.81). Furthermore, there were no differences in secondary study end points, and no apparent treatment effect in patients with previous chlamydia infection. CONCLUSION Three months' treatment with doxycycline did not improve pain or functional status in patients with chronic reactive or seronegative arthritis.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and European League Against Rheumatism</pub><pmid>11709448</pmid><doi>10.1136/ard.60.12.1088</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-4967 |
| ispartof | Annals of the rheumatic diseases, 2001-12, Vol.60 (12), p.1088-1094 |
| issn | 0003-4967 1468-2060 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1753446 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Anti-Bacterial Agents - adverse effects Anti-Bacterial Agents - therapeutic use Antibiotics Arthritis Arthritis - drug therapy Arthritis - physiopathology Arthritis, Reactive - drug therapy Arthritis, Reactive - physiopathology Biological and medical sciences Bones, joints and connective tissue. Antiinflammatory agents Case reports Chlamydia Chronic Disease Double-Blind Method Doxycycline Doxycycline - adverse effects Doxycycline - therapeutic use Drug therapy Evaluation Female Follow-Up Studies Health Status Indicators Humans Infections Laboratories Male Medical sciences Middle Aged Pain Pain Measurement Patient Compliance Patients Pharmacology. Drug treatments Physicians Quality of Life Questionnaires Randomised Controlled Trial Reiter's syndrome seronegative arthritis Surveys and Questionnaires Treatment Outcome Variance analysis |
| title | Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T15%3A14%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Randomised,%20blinded,%20placebo%20controlled%20trial%20of%20doxycycline%20for%20chronic%20seronegative%20arthritis&rft.jtitle=Annals%20of%20the%20rheumatic%20diseases&rft.au=Smieja,%20M&rft.date=2001-12-01&rft.volume=60&rft.issue=12&rft.spage=1088&rft.epage=1094&rft.pages=1088-1094&rft.issn=0003-4967&rft.eissn=1468-2060&rft.coden=ARDIAO&rft_id=info:doi/10.1136/ard.60.12.1088&rft_dat=%3Cgale_pubme%3EA80771926%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1778063099&rft_id=info:pmid/11709448&rft_galeid=A80771926&rfr_iscdi=true |